Amanda Feilding and Cosmo Feilding-Mellen: In Conversation at Breaking Convention 2024

Amanda Feilding and Cosmo Feilding-Mellen discuss their ongoing contributions to the psychedelic research landscape, bridging historical activism with modern drug development. Feilding details her work in promoting the therapeutic potential of LSD for conditions such as Alzheimer's, emphasizing the importance of blood flow in the brain. Her approach incorporates both experimental research and strategic policy advocacy, with a focus on translating these insights into actionable medical treatments. Cosmo Feilding-Mellen outlines the mission of Beckley Psytech, which aims to develop evidence-based, FDA-approved psychedelic medicines. He reports on efforts such as developing intranasal 5-MeO-DMT, intended to improve the clinical experience by shortening the duration of the psychedelic session while maintaining therapeutic efficacy. This work highlights current efforts to professionalize the sector, focusing on accessibility and regulatory integration into mainstream healthcare.